Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEK1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intraperitoneal, Subcutaneous, Parenteral
01
Overview
MEK1 siRNA is a small interfering RNA (siRNA) designed to specifically target and silence the expression of the MAP2K1 gene, which encodes the Mitogen-Activated Protein Kinase Kinase 1 (MEK1). MEK1 is a key component of the Ras-Raf-MEK-ERK signaling pathway, which is frequently dysregulated in various cancers, including bladder cancer. By inducing the degradation of MEK1 mRNA through the RNA interference (RNAi) pathway, MEK1 siRNA inhibits downstream ERK signaling, leading to reduced cell viability, migration, and invasion, and increased apoptosis in tumor cells. In research settings, it is often used to validate the functional roles of MEK1 or to mimic the effects of tumor-suppressive microRNAs that target the same pathway.
- Other names
- MAP2K1 siRNAMAP-2K1 siRNAMAP 2K1 siRNAsi-MEK1si-MEK-1si-MEK 1siRNA targeting MEK1
02
Targets
Mitogen-activated protein kinase kinase 1 messenger RNA (MAP2K1 mRNA)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)
Beyond the preview
Go deeper on MEK1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEK1 siRNA.